Concepedia

Shannon Ferrante

SF

Statistics

Publications

13

Citations

470

H-Index

11

Active since

2010

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Pittsburgh

Providence College

Novartis (United States)

Shannon Ferrante is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacoeconomics, and interferon-based therapy.

ORCID

Publications per year

2010–2022

13

Publications

13

Sustained Efficacy of the Pentavalent Rotavirus Vaccine, RV5, up to 3.1 Years Following the Last Dose of Vaccine

Timo Vesikari, Aino Karvonen, Shannon Ferrante et al. · The Pediatric Infectious Disease Journal · 2010 · 82 citations

, , +17

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study

Timo Vesikari, Aino Karvonen, Shannon Ferrante et al. · European Journal of Pediatrics · 2010 · 82 citations · Full text

, , +17

Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States

Jagpreet Chhatwal, Shannon Ferrante, Cliff Brass et al. · Value in Health · 2013 · 69 citations · Full text

, , +11

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

Shannon Ferrante, Jagpreet Chhatwal, Clifford A. Brass et al. · BMC Infectious Diseases · 2013 · 49 citations · Full text

, , +17

Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal

Elamin H. Elbasha, Jagpreet Chhatwal, Shannon Ferrante et al. · Applied Health Economics and Health Policy · 2013 · 38 citations

, , +12

1–5 of 13